5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Zydus Lifesciences Ltd.

•
zyduscadila.comBSE: 532321NSE: ZYDUSLIFE
Market Cap₹ 1,11,671 Cr.
Current Price
High / Low₹ 1,205 / 836
Stock P/E24.7
Book Value₹ 270
Price to Book3.23
Dividend Yield0.09 %
ROCE21.4 %
ROE19.7 %
Face Value₹ 1

Add ratio to table

ABOUT

KEY POINTS

Revenue Breakup Mar 2026 • Pharmaceuticals: 82.6% • Consumer Products: 14.6% • Medical Technologies: 2.9%

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Company has a healthy return on capital (ROCE) of 24.1%
  • Company has a good return on equity (ROE) track record: 3 Years ROE 20.4%
  • Company has consistently been profitable over the last 5 years
  • Working capital cycle has improved - days down from 64 to 30
  • Company comfortably covers its interest (16.1x coverage)
  • Company has a consistent dividend-paying track record

CONS

  • Recent results are weak - TTM profit is down 16.9% versus prior year
  • A large part of profit comes from other income (27.1% of PBT)
  • Receivables are growing faster than sales - a possible quality concern
  • Total debt has risen sharply - up 271.3% year on year
  • Recurring exceptional / one-off items are inflating headline profit

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTY NEXT 50NIFTY PHARMANIFTY100 QUALTY30NIFTYLARGEMIDCAP250NIFTY100 EQL WGT
S.No.Name
1.SUNPHARMA1842.0036.54441957.500.872901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9326.0084.64247576.000.32902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4975.0086.76189233.010.76566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1119.5024.74111670.550.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1365.0032.72110272.680.95785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1970.3597.37106460.420.10362.07123.942026.3129.1018.2031.50
7.DRREDDY1161.0030.0796906.380.69435.60-69.108099.80-5.2113.7510.63
8.AUROPHARMA1675.4525.9796401.690.241032.0325.229150.3517.4412.7620.54
9.LUPIN2096.0017.3495842.920.861416.9816.018276.8934.2828.8629.59
10.MANKIND2277.0046.0494050.370.04574.0929.124030.5912.8913.2426.30
11.GLENMARK2416.9037.9468210.880.10482.83927.884018.4831.3520.3520.03
12.BIOCON390.95128.6363712.890.13136.8053.364336.0010.893.2619.54
Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
5,0534,2594,3445,3666,0465,1145,1246,2906,4676,0386,7807,4348,017
3,6343,3053,4033,9094,1243,8213,8824,4024,5424,5225,0485,6786,798
Operating Profit1,4189549411,4581,9231,2931,2421,8881,9251,5161,7321,7571,219
OPM %28.07%22.39%21.66%27.17%31.80%25.28%24.24%30.01%29.76%25.11%25.55%23.63%15.20%
22136381626311458-13921248926382124
Interest18920353225327785101130123156
Depreciation180184195205215234229238238302360508555
Profit before Tax1,3291,0079261,5471,9001,2711,1841,6721,9211,6871,3531,6601,344
Tax %16.26%22.48%23.10%20.76%22.96%29.36%15.16%25.31%22.60%26.91%28.69%19.18%26.35%
Net Profit00001,4829201,0261,2441,5211,2391,0231,341990
10.757.927.5911.6614.119.0510.1811.6414.5812.5110.3612.659.35

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
9,37611,90513,16614,25314,40415,11017,23719,54723,24227,14828,270
7,4729,05810,18711,47311,01811,93513,66614,24816,34819,95822,045
Operating Profit1,9042,8472,9782,7803,3853,1753,5725,2996,8947,1906,224
OPM %20.31%23.92%22.62%19.51%23.50%21.01%20.72%27.11%29.66%26.48%22.02%
147133198-247-130503-1303552401,2781,021
Interest6311119634218612713081191439510
Depreciation3735395996966707137237649161,4081,725
Profit before Tax1,6152,3312,3821,4952,3992,8382,5904,8096,0276,6216,045
Tax %7.98%24.21%22.26%21.39%8.07%18.03%22.70%20.33%23.43%24.09%25.06%
Net Profit1,4861,7661,8521,1762,2062,3262,0023,8314,6155,0264,530
EPS14.5317.3518.0611.4920.8443.8319.3038.3644.9950.10—
Dividend Payout %22.03%20.18%19.39%30.46%16.80%5.70%30.97%7.82%24.45%2.00%—

COMPOUNDED SALES GROWTH

10 Years:
11%
5 Years:
14%
3 Years:
16%

COMPOUNDED PROFIT GROWTH

10 Years:
10%
5 Years:
19%
3 Years:
37%

STOCK PRICE CAGR

10 Years:
11%
5 Years:
15%
3 Years:
21%
1 Year:
7%

RETURN ON EQUITY

10 Years:
18%
5 Years:
18%
3 Years:
20%
Last Year:
20%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Corporate actions

2026

May 29

₹ 1260.00

Buy Back of Shares

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital102102102102102102101101101101
Minority Interest1561911,2931,3351,9372,0542,1722,2722,4052,471
6,8588,64210,28410,27312,89016,89717,41519,72923,85227,011
5,1515,3137,8907,5283,7433,7381,1521,8674,0809,353
Trade Payables1,5481,8881,9232,0442,2062,1382,1252,1272,2812,845
5101,0041,0211,5511,9321,7701,5281,5412,1398,517
Total Liabilities14,32517,14122,51322,83422,81026,70024,49427,63734,85850,298
5,7556,48312,16412,23012,13312,18811,52112,36813,13424,106
Capital Work in Progress1,5431,5278377427836611,1301,1121,3181,166
4357466747658303,2881,5471,2206,4127,540
1,8042,3852,6882,7893,2363,7193,4133,4423,9445,628
00000005,2204,0855,416
Cash & Bank1,5441,3155499658881,1075731,1052,9571,417
3,2454,6855,6015,3434,9405,7366,3103,1693,0095,026
Total Assets14,32517,14122,51322,83422,81026,70024,49427,63734,85850,298

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
1,5341,5521,9493,2343,6392,7793,2813,1966,7812,117
Cash from Investing-2,872-974-4,239-1,012-725-1,0001,535-1,475-8,358-8,296
Cash from Financing2,316521,885-1,528-2,548-868-4,400-1,7791,9955,807
756-3-1,07239122236-177-58419-373

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026

Shareholding Pattern

Numbers in percentages

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
74.9874.9874.9874.9974.9974.9975.0075.0075.01
5.597.527.537.317.137.347.066.956.88
12.5610.5910.6110.9511.0910.8611.0811.2011.27
Government0.000.000.000.000.000.000.000.000.00
6.796.856.846.686.746.806.856.866.83

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-11
Credit Rating

2026-09-11 - Zydus Lifesciences Limited has informed the Exchange about Credit Rating

2026-09-11
Analysts/Institutional Investor Meet/Con. Call Updates

2026-09-11 - Zydus Lifesciences Limited has informed the Exchange about Schedule of meet

2026-09-09
Copy of Newspaper Publication

2026-09-09 - Zydus Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication

2026-09-05
General Updates

2026-09-05 - Zydus Lifesciences Limited has informed the Exchange about General Updates

2026-09-01
General Updates

2026-09-01 - Zydus Lifesciences Limited has informed the Exchange about General Updates

2026-08-31
Press Release

2026-08-31 - Zydus Lifesciences Limited has informed the Exchange regarding a press release dated August 31, 2026, titled "Zydus Announces Positive Topline Results from Completed EVIDENCES-X Phase II(b) Clinical Trial of Saroglitazar Mg in MASH".

2026-08-26
General Updates

2026-08-26 - Zydus Lifesciences Limited has informed the Exchange about General Updates

2026-08-25
General Updates

2026-08-25 - Zydus Lifesciences Limited has informed the Exchange about General Updates

2026-08-24
Updates

2026-08-24 - Zydus Lifesciences Limited has informed the Exchange regarding 'Disclosure under SEBI (Prohibition of Insider Trading) Regulations, 2015'.

News

Recent coverage and analyst commentary for ZYDUSLIFE

Loading news…

🤖

AI Stock Analyst

Zydus Lifesciences Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login